China News Service, Guangzhou, June 5 (Cai Minjie, Li Tingting) The Guangdong Provincial Drug Administration issued a notice on the evening of the 5th that drug retail companies in medium and high-risk areas in the province suspend the sale of drugs in the "List of Drugs that Need to be Registered and Reported During the Epidemic" until they resume as Low-risk areas.
The list of drugs that require real-name registration during the above-mentioned epidemic is divided into two categories: Chinese patent medicines and chemical drugs. Chinese patent medicines include Fenghan Ganmao Granules, (Compound) Ganmaoling (all oral dosage forms), Ganmao Qingre Granules, etc.; chemical medicines include argaphene Powder, Analgin tablets and Paracetamol Ganamin tablets, etc.
According to the notice, Guangdong pharmaceutical retail companies must further implement the real-name registration and reporting system for drugs in the "Catalog", requiring customers to enter the store to measure their body temperature and show their health code. If a customer’s health code "yellow code" is found, they are not allowed to enter the store to purchase drugs, and Guide to a medical institution for treatment.
Pharmaceutical retail companies should post relevant requirements and warning signs in conspicuous locations in their business premises, and publicize the aforementioned measures to the public.
In addition, from now on, Guangdong drug network sales companies are not allowed to sell "Catalog" drugs to individual consumers whose delivery addresses are in Guangzhou, Shenzhen, and Foshan, until the epidemic situation in the region is effectively controlled, and the specific recovery time will be notified separately.
The Guangdong Provincial Food and Drug Administration stated that the current situation of epidemic prevention and control in Guangdong is severe, and it is necessary to give full play to the "sentinel" early warning role of drug retail companies in the province to improve the sensitivity and targeting of monitoring.
(Finish)